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Abstract
Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial
growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced
gastric cancer (GC). In the present study, we aimed to evaluate the efficacy and safety of angiogenesis inhibitors in
advanced GC. We searched published randomized controlled trials (RCTs) comparing angiogenesis inhibitors with
non-angiogenesis inhibitors for the treatment of GC. MEDLINE, EMBASE, and the Cochrane Controlled Trials Register
were searched. The extracted data on progression-free survival (PFS) and overall survival (OS) were measured in
terms of hazard ratios (HR) and corresponding 95 % confidence intervals (CIs). In addition, risk ratios (RR) and
corresponding 95 % CIs were pooled for objective response rate (ORR), disease control rate (DCR), and risk of
adverse events (AEs). Ten RCTs involving 2786 patients were included. Compared with non-angiogenesis inhibitor-
containing regimens, angiogenesis inhibitor-containing regimens resulted in a significant improvement in OS (HR 0.80,
95 % CI 0.69–0.93, P = 0.004), prolonged PFS (HR 0.66, 95 % CI 0.51–0.86, P = 0.002), and superior ORR (RR 1.34, 95 % CI
1.09–1.65, P = 0.005) and DCR (RR 1.37, 95 % CI 1.17–1.61, P = 0.0001). Angiogenesis inhibitors were associated with a
greater number of AEs, but most of these were predictable and manageable. However, hand-foot syndrome, diarrhea,
and gastrointestinal (GI) perforation were significantly increased in patients treated with angiogenesis inhibitors. In
summary, angiogenesis inhibitor-containing regimens were superior to non-angiogenesis inhibitor-containing
regimens in terms of OS, PFS, RR, and DCR in patients with advanced GC.
Keywords: Angiogenesis, Gastric cancer, Monoclonal antibodies, Tyrosine kinase inhibitors
Background
Gastric cancer (GC) is the fifth most common malignancy
worldwide and is the third leading cause of cancer deaths
in both sexes, accounting for 723,000 deaths (8.8 % of the
total), with the highest estimated mortality rates in East
Asia and the lowest in North America [1–3]. Despite a
significant decline in incidence worldwide over the last
few decades, unfortunately, most GC patients are diag-
nosed at an advanced stage with 5-year overall survival
(OS) rates for all stages combined generally below 30 %.
Palliative systemic chemotherapy usually represented by a
platinum-based doublet is the mainstay of treatment in
advanced stages. The addition of a third drug such as an
anthracycline or a taxane has been shown to improve
response rate and provide modest survival benefits at the
cost of significant toxicity. Progress in understanding GC
cancer biology has led to the development of treatment
targeting the epidermal growth factor receptor (EGFR),
human epidermal growth factor receptor-2 (HER-2), and
angiogenesis, which has changed the therapeutic paradigm
of GC.
Recent studies have shown that angiogenesis in GC is
a key step in metastasis. It has been confirmed that the
vascular endothelial growth factor (VEGF) family is a
crucial mediator of angiogenesis [4]. Approximately
50 % of GCs express VEGF, and the overexpression of
VEGF-A and VEGF-D in GC is associated with a poor
prognosis [4, 5]. Two categories of agents have been
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developed to target this family: antibody-based agents
and VEGF receptor (VEGFR) tyrosine kinase inhibitors
(TKIs) [6–8].
Many clinical trials have demonstrated that GC pa-
tients can benefit from angiogenesis inhibitors [9–14].
Ramucirumab (a type of monoclonal antibody) or apati-
nib (a type of TKI), which binds to VEGFR-2, are re-
ported to increase progression-free survival (PFS) and
OS in patients treated with one or two previous lines of
therapy [9–11, 13]. However, many phase I/II studies of
anti-angiogenic TKIs do not show satisfactory outcomes
when added to chemotherapy [15–21]. The major stud-
ies of angiogenesis inhibitors for gastric cancer were
showed in Additional file 1: Table S5. Therefore, the
overall efficacy and safety of anti-angiogenic agents in
GC are still unknown. In this study, we performed an
updated meta-analysis to summarize the efficacy and




An electronic search of the PubMed, MEDLINE,
Cochrane Central Register of Controlled Trials (CEN-
TRAL), and EMBASE databases as well as the American
Society of Clinical Oncology (ASCO) and the European
Society of Medical Oncology (ESMO) databases was per-
formed from inception to February 2016. The detailed
search strategy is described in Fig. 1. The search strategy
included a combination of the MeSH term “angiogenesis
inhibitors” OR the keywords “angiogenetic inhibitors,”
“angiogenic antagonists,” “angiogenic inhibitors,” “angio-
static agents,” “antiangiogenetic agents,” “angiogenesis
factor inhibitor”; the MeSH term “gastric neoplasms”
OR the keywords “gastric tumor*,” “gastric neoplasm*,”
“gastric cancer*”. All potentially relevant studies were
retrieved, and their references were checked for add-
itional eligible studies. Furthermore, we also searched
http://www.clinicaltrials.gov/ for information on regis-
tered RCTs to identify trials registered as completed but
whose results had not yet been published. This review
was conducted and reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) Statement issued in 2009.
Definition of angiogenesis inhibitors
We defined angiogenesis inhibitors as those drugs which
targeted VEGF and its receptors, which are the key me-
diators of angiogenesis.
Inclusion criteria
Studies which met the following criteria were included:
(1) patients must be cytologically or pathologically con-
firmed as having GC at a clinically advanced stage; (2)
randomized controlled trials (RCTs) comparing angio-
genesis inhibitors with non-angiogenesis inhibitors were
deemed eligible; (3) one or more of the following were
reported in the trials: overall response rate (ORR) (the
sum of complete [CR] and partial responses [PR]),
Fig. 1 Flow chart of search process
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disease control rate (DCR) (the sum of CR, PR and
stable disease [SD]), PFS, OS, and adverse events.
Data extraction
Two independent investigators extracted data from the
included studies on the basis of PRISMA [22]. When the
two investigators disagreed, a third investigator partici-
pated in the discussion to resolve the disagreement. In-
formation collected from these trials included the first
author, year of publication, study design, number of pa-
tients, median age, ECOG performance status, thera-
peutic regimen, drug doses, and outcomes. Clinical
outcomes collected from the trials included median PFS
and OS, hazard ratios (HR) for OS and PFS and their 95
% confidence intervals (CIs), DCR and ORR, risk ratios
(RR) for DCR and ORR, and their 95 % CIs, numbers,
and rate of each type of adverse event stratified by sever-
ity. The response was evaluated according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST,
version 1.1) and classified as a CR, PR, SD, or progres-
sive disease (PD). ORR was defined as CR plus PR and
DCR was defined as ORR plus SD.
Quality assessment
The risk of bias in each study was assessed using the
Cochrane Collaboration tool. The following evaluation
domains were assessed accordingly: randomization se-
quence generation, allocation concealment, blinding of
participants and study personnel, blinding of outcome
assessors, incomplete outcome data, selective reporting,
and other biases. The risk of each domain was rated as
high risk, unclear risk, or low risk according to the
match level between information extracted and evalu-
ation criteria.
Statistical analysis
A statistical analysis was conducted, and forest plots
were performed using Review Manager 5.3. RRs and
their 95 % CIs were calculated for DCR, ORR, and grade
3 and 4 toxicity as dichotomous outcomes. HRs were
summarized and their corresponding standard errors
were computed to analyze the time-to-event data as gen-
eric inverse variance outcomes. The inverse variance al-
gorithm and Mantel-Haenszel algorithm were used.
Heterogeneity between studies was assessed with
Cochrane’s X2 statistics and the inconsistency statistic
(I2). We considered I2 < 50 % as low-level heterogeneity
and I2 > 50 % as significant heterogeneity. A fixed-effect
model was used when I2 < 50 % and a random-effect
model was used when I2 > 50 %. P values <0.05 were
regarded as statistically significant in all included
studies.
Results
Characteristics of the included studies
Figure 1 shows the flow chart of study selection. A total
of 60 relevant studies were identified by comprehensive
search, and two conference abstracts were obtained by
manual searching of the ASCO. Fifteen articles were ex-
cluded as they were duplicates, leaving 45 articles poten-
tially eligible for inclusion, of which 15 were eliminated
after reading the abstracts and titles. The full texts of the
remaining 30 articles were then reviewed, and ten trials
[9–11, 13, 18, 23–27] involving 2786 patients were fi-
nally included in the meta-analysis. The sample size in
the included trials varied from 91 to 774, the median age of
the enrolled patients ranged from 52 to 65 years. Of these,
two studies [25, 26] enrolled patients who were treated
with anti-VEGF-based drugs, five studies [9–11, 13, 27] en-
rolled patients who were treated with anti-VEGFR-2
agents, and three trials [18, 23, 24] enrolled patients who
were treated with inhibitors of multiple tyrosine kinases
(one of the targets is VEGFR-2). Four trials [18, 25–27]
were conducted in the first-line setting and the other six
trials [9–11, 13, 23, 24] in the pretreatment setting. Table 1
and Fig. 2 summarize the characteristics and qualities of
both the included agents and articles.
Assessment of methodological quality
We critically appraised the methodological quality of
the included studies in accordance with the Cochrane
Collaboration Risk of Bias Tool. All included trials
were rated as low bias risk in randomization, as the
authors stated the principles of randomization in
detail. Other bias sources were not identified. The
graphical results of methodological quality are shown
in Fig. 2.
Overall survival (OS) and progression-free survival (PFS)
All included studies [9–11, 13, 18, 23–27] reported OS,
and nine trials [9–11, 13, 18, 24–27] reported PFS. One
study [23] reported time to progression (TTP). Of the
ten trials, four [9–11, 13] reported a statistically signifi-
cant improvement in OS and five trials [9–11, 13, 25]
showed improved PFS. The median OS in the angiogen-
esis inhibitor groups reported in ten trials ranged from
4.27 to 12.1 months, and the median PFS varied from
2.1 to 9.6 months. The pooled results showed that when
compared to the non-angiogenesis inhibitor groups,
treatment with angiogenesis inhibitors were associated
with a significantly prolonged OS (HR 0.80, 95 % CI
0.69–0.93, P = 0.004 Fig. 3a) and increased PFS (HR
0.66, 95 % CI 0.51–0.86, P = 0.002, Fig. 3b). Significant
heterogeneity was detected among the studies in Fig. 3a
(P = 0.006, I2 = 61 %) and Fig. 3b (P < 0.00001, I2 = 88 %),
so we conducted a sensitivity analysis. We excluded the
study of Atsushi Ohtsu that had the maximum relative
Yu et al. Journal of Hematology & Oncology  (2016) 9:111 Page 3 of 15
Table 1 Characteristics of the included studies
Study Agents Year Phase Line Regimens No. of patients Median age (years) mOS (months) mPFS (months) DCR (%) ORR (%)
Charles S. Fuchs Ram 2014 3 2 Ram + BSC 238 60 5.20 2.10 49 3
Placebo + BSC 117 60 3.80 1.30 23 3
P = 0.76 P < 0.0001
Hansjochen Wilke Ram 2014 3 2 Ram + PTX 330 61 9.60 4.40 80 28
Placebo + PTX 335 61 7.40 2.90 64 16
P < 0.0001 P = 0.0001
Harry H. Ram 2014 2 1 Ram + mFOLFOX6 84 65 6.40 11.70 85 45
Placebo + mFOLFOX6 84 60 6.70 11.50 67 46
P = 0.008
Jin Li Apatinib 2013 2 >2 Apatinib 47 55 4.83 3.67 7.32 6.38
Apatinib 46 53 4.27 3.20 15 13.04
Placebo 48 54 2.50 1.40 0 0
Shukui Qin Apatinib 2016 3 >2 Apatinib 176 58 6.50 2.60 42.05 2.84
Placebo 91 58 4.70 1.80 8.79 0
P = 0.1695 P < 0.001
Atsushi Ohtsu Bev 2011 3 1 Bev + CDP + Cap 387 58 12.10 6.70 76.9 46
Placebo + CDP + Cap 387 59 10.10 5.30 67.7 37.4
P = 0.0315
Lin Shen Bev 2015 3 1 Bev + CDP + Cap 100 54.2 10.50 6.30 75.3 41
Placebo + CDP + Cap 102 55.5 11.40 6.00 72.1 34
P = 0.35
Markus Hermann Moehler Sunitinib 2013 2 2 Sunitinib + FOLFIRI 45 NR 10.50 3.60 58 20
Placebo + FOLFIRI 46 NR 9.00 3.30 56 29
JH Yi Sunitinib 2012 2 2 Sunitinib + docetaxel 56 54 8.00 3.90 (TTP) 75 41.1
Docetaxel 49 52 6.60 2.60 (TTP) 51 14.3
W Koizumi TSU-68 2013 2 1 TSU-68 + S-1/CDDP 45 62 16.6 6.9 NR 62.2
S-1/CDDP 46 63.5 15.45 7.1 NR 56.5
Ram Ramucirumab, BSC best supportive care, mOS median overall survival, mPFS median progression-free survival, HR hazard ratio, DCR disease control rate, ORR objective response rate, PTX paclitaxel, Bev















Fig. 2 Assessment of risk of bias. a Risk of bias summary. b Risk of bias graph
Fig. 3 Forest plot and pooled HR and 95 % CI for OS (a) and PFS (b): anti-angiogenesis therapy versus non-anti-angiogenesis therapy. The pooled
HR for OS and PFS showed that the patients receiving anti-angiogenesis therapy possessed a significant improvement in OS and PFS. HR hazard
ratios, OS overall survival, PFS progression-free survival, CI confidence intervals
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weight (about 15.0 %) in Fig. 3a, the study of Moehler HM
which had the minimum relative weight (about 6.2 %) in
Fig. 3a, the study of Atsushi Ohtsu that had the maximum
relative weight (about 12.9 %) in Fig. 3b, and the study of
W Koizumi which had the minimum relative weight (about
9.0 %) in Fig. 3b, and the survival outcome was similar.
In the subgroup analyses of medication administered,
both treatment with angiogenesis inhibitors alone (HR
0.61, 95 % CI 0.42–0.89, P = 0.01, Fig. 4a) and angiogen-
esis inhibitors combined with chemotherapy (HR 0.88,
95 % CI 0.79–0.97, P = 0.01, Fig. 4b) led to significantly
improved OS, but only the treatment with angiogenesis
inhibitors alone prolonged PFS (HR 0.36, 95 % CI 0.22–
0.57, P < 0.0001, Fig. 5a). With regard to the line of
treatment, a significant PFS (HR 0.50, 95 % CI 0.34–
0.73, P = 0.0004, Fig. 5d) and OS (HR 0.71, 95 % CI
0.58–0.88, P = 0.002, Fig. 4d) benefit was found in ≥ the
second-line treatment. Disappointingly, no PFS (HR
0.87, 95 % CI 0.75–1.01, P = 0.08, Fig. 5c) and OS (HR
0.92, 95 % CI 0.80–1.06, P = 0.23, Fig. 4c) benefits were
observed with the first-line treatment. When stratified
by drug class, anti-VEGF-based agents led to longer PFS
(HR 0.82, 95 % CI 0.71–0.93, P = 0.003, Fig. 5e) but did
not significantly improve OS (HR 0.94, 95 % CI 0.75–
1.17, P = 0.57, Fig. 4e) compared with non-angiogenesis
inhibitors. Anti-VEGFR-2 and multiple receptor inhibi-
tor based agents resulted in longer PFS (HR 0.61, 95 %
CI 0.43–0.88, P = 0.007, Fig. 5f ) and OS (HR 0.75, 95 %
CI 0.63–0.90, P = 0.002, Fig. 4f ). Besides, due to the inci-
dence of GC is region-specific and treatment approaches
are different between eastern and western countries, so
the patients enrolled in the study were also divided into
two subgroups: the Asian group and the non-Asian
group. Angiogenesis inhibitors increased PFS in both
Asian patients (HR 0.62, 95 % CI 0.42–0.93, P = 0.02,
Additional file 2: Figure S1C) and non-Asian patients
(HR 0.61, 95 % CI 0.53–0.69, P < 0.00001, Additional file
2: Figure S1D), but only improved OS (HR 0.82, 95 % CI
0.70–0.95, P < 0.007, Additional file 2: Figure S1C) in
non-Asian patients.
Overall response rate (ORR) and disease control rate (DCR)
All ten trials reported ORR, and nine studies reported
DCR. The DCR ranged from 0 to 85 %, and the ORR
varied from 0 to 46 % in the angiogenesis inhibitors
group. The pooled data showed that angiogenesis inhibi-
tors resulted in superior ORR (HR 1.34, 95 % CI 1.09–
1.65, P = 0.005, Fig. 6b) and a high DCR (HR 1.37, 95 %
CI 1.17–1.61, P = 0.0001, Fig. 6a) compared with non-
angiogenesis inhibitors.
Subgroup analysis of medication administration
indicated that both angiogenesis inhibitors alone and
angiogenesis inhibitors combined with chemotherapy
led to a statistically significant improvement in DCR
(RR 2.93, 95 % CI 1.79–4.80, P < 0.0001, Fig. 7a and
RR 1.19, 95 % CI 1.10–1.29, P < 0.0001, Fig. 7b).
However, we only found an improvement in ORR (RR
1.29, 95 % CI 1.14–146, P < 0.0001, Fig. 8B) for pa-
tients treated with angiogenesis inhibitors combined
with chemotherapy. In addition, angiogenesis inhibi-
tors increased DCR and ORR in both the first-line
(RR 1.13, 95 % CI 1.02–1.26, P = 0.02, Fig. 7c and RR
1.16, 95 % CI 1.00–1.33, P = 0.04, Fig. 8d) and ≥ the
second-line therapy (RR 1.81, 95 % CI 1.27–2.58, P =
0.001, Fig. 7d and RR 1.75, 95 % CI 1.36–2.25, P <
0.0001, Fig. 8d). When stratified by drug class, im-
provement in ORR and DCR were observed with both
anti-VEGF-based drugs (RR 1.22, 95 % CI 1.02–1.45,
P = 0.03, Fig. 8e and RR 1.10, 95 % CI 1.00–1.21, P =
0.04, Fig. 7e) and anti-VEGFR-2-based and multiple
receptor tyrosine kinase inhibitor drugs (RR 1.42, 95 % CI
1.19–1.70, P < 0.0001, Fig. 8f and RR 1.63, 95 % CI 1.27–
2.09, P = 0.0001, Fig. 7f).
Safety
The toxicity reported in the included studies, summa-
rized according to the National Cancer Institute Com-
mon Toxicity Criteria is shown in Table 2 (only grade
≥3 toxicities are presented). In general, grade ≥3 adverse
events were more frequent in patients treated with
angiogenesis inhibitors and included hand-foot syn-
drome, hemorrhage, hypertension, proteinuria, and GI
perforation for anti-angiogenic-induced events, and neu-
tropenia, leukopenia, and fatigue for chemotherapy-
induced events. In addition, hand-foot syndrome (RR
2.17, 95 % CI 1.48–4.97, P = 0.001, Table 2), diarrhea (RR
1.66, 95 % CI 1.11–2.50, P = 0.01, Table 2), and GI per-
foration (RR 4.13, 95 % CI 1.14–15.05, P = 0.03, Table 2)
were significantly increased in patients treated with
angiogenesis inhibitors. However, anemia (RR 0.73, 95 %
CI 0.54–0.98, P = 0.03, Table 2) was less frequent in the
angiogenesis inhibitor group. The RRs of grade ≥3
adverse events are summarized in Table 2.
Discussion
GC is one of the most common malignant tumors of the
digestive tract worldwide. With the development of
therapeutic strategies, the survival time of GC patients
has significantly increased over the past 20 years. How-
ever, the prospects for the treatment of GC are not opti-
mistic. Chemotherapy is currently the main treatment
for advanced GC; however, there is no standard first-line
chemotherapy regimen for advanced GC. Moreover,
traditional chemotherapy has reached an efficacy plat-
eau. Therefore, it is necessary to identify a more effective
treatment for advanced GC.
In the last 10 years, the rapid development of molecu-
lar biology has provided new directions for the
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treatment of GC. Many studies on immunotherapy and
anti-angiogenic therapy are underway [28]. For example,
the results of KEYNOTE-012 and KEYNOTE-028
indicated that pembrolizumab, a type of anti-PD-1 anti-
body, may be a promising agent in pretreated and PD-
L1-positive advanced GC. However, there is still a long
Fig. 4 Forest plot and pooled HR and 95% CI for subgroup OS: anti-angiogenesis therapy versus non-anti-angiogenesis therapy. HR hazard ratios,
CI confidence intervals, OS overall survival. (a: OS of subgroups of angiogenesis inhibitors alone threapy; b: OS of subgroups of angiogenesis in-
hibitors combined with chemotherapy threapy; c: OS of subgroups of the first line threapy; d: OS of subgroups of the second line threapy; e: OS
of subgroups of anti-VEGF threapy; f: OS of subgroups of anti-VEGFR and multiple receptor inhibitors threapy)
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way to go before patients can benefit from this treat-
ment. Among the novel target treatment strategies, the
most widely studied, the most extensive, and the most
in-depth is the study of angiogenesis. The angiogenic
pathway modulated by the VEGF family has been
extensively studied in many tumors [29]. Angiogenesis
contributes to the progression, invasion, and metastasis
of malignancy and the importance of anti-angiogenesis
therapy in inhibiting malignant tumor growth has been
confirmed. Targeting the VEGF pathway in GC started
Fig. 5 Forest plot and pooled HR and 95 % CI for subgroup PFS: anti-angiogenesis therapy versus non-anti-angiogenesis therapy. HR hazard ratios,
CI confidence intervals, PFS progression-free survival. (a: PFS of subgroups of angiogenesis inhibitors alone threapy; b: PFS of subgroups of
angiogenesis inhibitors combined with chemotherapy threapy; c: PFS of subgroups of the first line threapy; d: PFS of subgroups of the second
line threapy; e: PFS of subgroups of anti-VEGF threapy; f: PFS of subgroups of anti-VEGFR and multiple receptor inhibitors threapy)
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to receive more attention when the results from phase III
trials confirmed its efficacy in inducing superior survival
outcome beyond standard therapy [9, 10, 13]. Ramuciru-
mab, a monoclonal antibody, can selectively bind to
VEGFR-2 and block the downstream effects of the VEGF
pathway in angiogenesis. The REGARD [9] and RAIN-
BOW [10] studies reported that advanced GC patients
may benefit from treatment with ramucirumab (HROS
0.776, 95 % CI 0.603–0.998, P = 0.047, HROS 0.807, 95 %
CI 0.678–0.962, P < 0.0001, respectively, and HRPFS 0.483,
95 % CI 0.376–0.620, P < 0.0001, HRPFS 0.635, 95 % CI
0.536–0.752, P < 0.0001, respectively). The survival bene-
fits in the REGARD and RAINBOW studies led to the ap-
proval of ramucirumab by the FDA for the treatment of
advanced GC. Apatinib, a small molecule oral TKI, can in-
hibit the intracellular function of VEGFR by blocking the
receptors of tyrosine kinases expressed by endothelial
cells. A phase II [11] and phase III [13] trial explored the
effects of apatinib in patients with advanced GC and the
results showed that the patients benefited from apatinib
treatment. Bevacizumab, a monoclonal antibody, can bind
VEGF-A ligand, thus inhibiting VEGF-mediated angiogen-
esis. The results of the AVAGAST [25] study showed that
bevacizumab can improve ORR (HR 8.61, 95 % CI 0.6–
16.6, P = 0.0315) and prolong PFS (HR, 0.80; 95 % CI
0.68–0.93, P = 0.0037), but there was no significant differ-
ence in OS (HR 0.87, 95 % CI 0.73–1.03, P = 0.1002) when
compared with the placebo. In addition, the outcomes of
the AVATAR [26] study were similar to those of the
AVAGAST study.
Fontana et al. [30] summarized the clinical efficacy of
bevacizumab and ramucirumab in advanced GC and dis-
cussed the results of clinical trials but paid little attention
on other angiogenic inhibitors, such as apatinib and suni-
tinib. Aprile et al. [31] mainly focused on the current sta-
tus of novel angiogenesis inhibitors in advanced GC, the
underlying biology, their mechanism of action, and recent
clinical trial results. They suggested that VEGFR-2 plays a
key role in GC, and VEGFR-2 blockade may be associated
with improved outcomes. Future efforts in translational
research should aim to clarify which patients may benefit
from the anti-angiogenic therapy. The aforementioned re-
views extensively describe the major clinical results of the
angiogenic inhibitors, their efficiency and disadvantages in
advanced GC. However, they are all narrative reviews and
may lead to a number of methodological flaws without a
clear and objective methods section. Furthermore, there is
still controversy regarding the effects of angiogenesis in-
hibitors on advanced GC. Hence, we performed this up-
dated meta-analysis to provide valuable clues for the
clinical application of angiogenesis inhibitors.
According to the current results, regimens containing
angiogenesis inhibitors showed substantial improve-
ments in OS (HR 0.80, 95 % CI 0.69–0.93, P = 0.004,
Fig. 3a), PFS (HR 0.66, 95 % CI 0.51–0.86, P = 0.002,
Fig. 3b), ORR (HR 1.34, 95 % CI 1.09–1.65, P = 0.005,
Fig. 6b), and DCR (HR 1.37, 95 % CI 1.17–1.11, P =
0.0001, Fig. 6a) compared with regimens without angio-
genesis inhibitors. Subgroup analyses showed that OS
was significantly improved following treatment with
Fig. 6 Forest plot and pooled RR and 95 % CI for DCR (a) and ORR (b): anti-angiogenesis therapy versus non-anti-angiogenesis therapy. The
pooled RR for DCR and ORR showed that the patients receiving anti-angiogenesis therapy had superior DCR and ORR. RR risk ratios, CI confidence
intervals, ORR overall response rate, DCR disease control rate
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angiogenesis inhibitor monotherapy (HR 0.61, 95 % CI
0.42–0.89, P = 0.01, Fig. 4a) or combined with chemo-
therapy (HR 0.88, 95 % CI 0.79–0.97, P = 0.01, Fig. 4b)
when compared with placebo and chemotherapy alone.
However, angiogenesis inhibitor monotherapy was un-
able to prolong PFS (HR 0.86, 95 % CI 0.71–1.03, P =
Fig. 7 Forest plot and pooled RR and 95 % CI for subgroup DCR: anti-angiogenesis therapy versus non-anti-angiogenesis therapy. RR risk ratios,
CI confidence intervals, DCR disease control rate. (a: DCR of subgroups of angiogenesis inhibitors alone threapy; b: DCR of subgroups of
angiogenesis inhibitors combined with chemotherapy threapy; c: DCR of subgroups of the first line threapy; d: DCR of subgroups of the second
line threapy; e: DCR of subgroups of anti-VEGF threapy; f: DCR of subgroups of anti-VEGFR and multiple receptor inhibitors threapy)
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Fig. 8 Forest plot and pooled RR and 95 % CI for subgroup ORR: anti-angiogenesis therapy versus non-anti-angiogenesis therapy. RR risk ratios,
CI confidence intervals, ORR overall response rate. (a: ORR of subgroups of angiogenesis inhibitors alone threapy; b: ORR of subgroups of
angiogenesis inhibitors combined with chemotherapy threapy; c: ORR of subgroups of the first line threapy; d: ORR of subgroups of the second
line threapy; e: ORR of subgroups of anti-VEGF threapy; f: ORR of subgroups of anti-VEGFR and multiple receptor inhibitors threapy)
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0.1, Fig. 5a) in patients with advanced GC. The reason
may be the anti-VEGF-based drugs combined with
chemotherapy can prolong PFS (HR 0.82, 95 % CI
0.71–0.93, P = 0.003), while anti-VEGFR-2 and mul-
tiple tyrosine kinase receptor inhibitors combined
with chemotherapy failed to improve PFS (HR 0.92,
95 % CI 0.65–1.03, P = 0.63). With regard to the line of
treatment, the efficacy of angiogenesis inhibitor therapy
may be different in the first-line and ≥ the second-line set-
ting. Significant PFS (HR 0.50, 95 % CI 0.34–0.73, P =
0.0004, Fig. 5d), OS (HR 0.71, 95 % CI 0.58–0.88, P =
0.002, Fig. 4d), ORR (RR 1.75, 95 % CI 1.36–2.25, P <
0.0001, Fig. 8d), and DCR (RR 1.81, 95 % CI 1.27–2.58, P
= 0.001, Fig. 7d) benefits were observed in ≥ the second-
line setting. However, there were ORR (RR 1.16, 95 % CI
1.00–1.33, P = 0.04, Fig. 8c) and DCR (RR 1.13, 95 % CI
1.02–1.26, P = 0.02, Fig. 7c) gains, but no OS (HR 0.92, 95
% CI 0.80–1.06, P = 0.23, Fig. 4c) and PFS (HR 0.87, 95 %
CI 0.75–1.01, P = 0.08, Fig. 5c) benefits in the first-line set-
ting. This may be due to the results of the most RCTs
showed no significant survival benefits regarding OS and
PFS, which included in this meta-analysis. With respect to
the anti-angiogenic drug class, subgroup analysis showed
that anti-VEGFR-2 and multiple tyrosine kinase receptor
inhibitor treatment was more efficacious than anti-VEGF
treatment in terms of OS, PFS, ORR, and DCR. One pos-
sible explanation is the differences in the targets of the
angiogenesis inhibitors. Anti-VEGFR-2 and multiple
tyrosine kinase receptor inhibitor drugs selectively bind to
VEGFR-2, which plays a key role in the VEGF/VEGFR
pathway. Anti-VEGF drugs only bind to VEGF-A and thus
cannot block other members of the VEGF family binding
to VEGFR-2. Another possible reason is related to the two
clinical trials included in the anti-VEGF subgroup, which
included patients treated with bevacizumab who had
negative survival outcomes. Ramucirumab and apatinib
were included in the VEGFR-2 and multiple tyrosine kin-
ase receptor inhibitor group. The mechanistic advantage
of ramucirumab, which binds to VEGFR-2 and has a long
half-life, may be better than bevacizumab. In addition, the
recent phase III study of apatinib [13], an oral small mol-
ecule VEGFR-2 TKI, in Chinese patients with advanced
GC, demonstrated prolonged median OS in the apatinib
arm of 195 versus 140 days in the placebo arm (HR 0.71,
95 % CI 0.54–0.94, P < 0.0001). The reason for these dif-
ferences is a current challenge, and further studies may
elucidate the pharmacological differences and possibly im-
prove clinical outcome.
As the incidence of GC is region-specific, and treat-
ment approaches are different between eastern and west-
ern countries, we divided the patients into two
subgroups: the Asian group and the non-Asian group.
The results show that angiogenesis inhibitors increased
PFS in both Asian patients (HR 0.62, 95 % CI 0.42–0.93,
P = 0.02, Additional file 2: Figure S1C) and non- Asian
patients (HR 0.61, 95 % CI 0.53–0.69, P < 0.00001,






Events/total RR (95 % CI) P value Analysis
modelTreatment group Control group
Decreased appetite 5 55/1095 60/973 0.86 (0.61, 1.22) 0.39 Fixed
Vomiting 5 62/1051 67/975 0.94 (0.48, 1.82) 0.84 Random
Anemia 8 118/1419 125/1161 0.91 (0.55, 1.50) 0.7 Random
Hypertension 6 105/1318 22/1066 2.85 (0.87–9.30) 0.08 Random
Hemorrhage 4 27/898 31/698 0.65 (0.39–1.09) 0.11 Fixed
Thromboembolic events 4 42/778 56/598 0.68 (0.46, 1.00) 0.05 Fixed
Proteinuria 5 147/1218 141/529 1.07 (0.76–1.34) 0.94 Fixed
GI perforation 3 12/985 2/496 4.1 (1.14–15.05) 0.03 Fixed
Neuropathy 3 30/318 27/312 1.11 (0.68–1.82) 0.67 Fixed
Diarrhea 7 60/1135 35/1044 1.66 (1.11, 2.50) 0.01 Fixed
Nausea 6 45/996 58/952 0.77 (0.53, 1.11) 0.16 Fixed
Fatigue 7 79/904 55/627 0.91 (0.44, 1.88) 0.75 Random
Leukopenia 6 83/797 45/665 1.23 (0.61, 2.48) 0.58 Random
Thrombocytopenia 5 33/797 16/665 1.74 (0.96, 3.12) 0.07 Fixed
Neutropenia 7 217/842 118/711 1.53 (0.99, 2.37) 0.06 Random
Hand-foot syndrome 4 51/711 14/569 2.83 (1.57, 5.11) 0.0005 Fixed
Electrolyte disturbance 3 23/662 26/574 0.8 (0.32–1.99) 0.63 Fixed
Pain 6 42/694 31/676 1.06 (0.30, 3.79) 0.93 Random
Liver damage 4 56/414 19.287 1.59 (1.01, 2.51) 0.04 Fixed
RR risk ratios, GI gastrointestinal
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Additional file 2: Figure S1D) but only improved OS in
non-Asian patients (HR 0.82, 95 % CI 0.70–0.95, P <
0.007, Additional file 2: Figure S1B). Given that angio-
genesis is a host mechanism, the observed differences
between Asian patients and non-Asian patients may be
attributed to the inherent differences in these ethnic
populations. This should be confirmed in future clinical
trials by focusing on the influence of racial/ethnic
factors.
Another focus in the treatment of GC patients is safety
and tolerability. Angiogenesis inhibitors have more ad-
verse reactions, such as hemorrhage, hypertension, and
proteinuria, and most are predictable and manageable
[12]. However, hand-foot syndrome (RR 2.83, 95 % CI
1.57–5.11, P = 0.0005), diarrhea (RR 1.66, 95 % CI
1.11–2.50, P = 0.01), and GI perforation (RR 4.10, 95
% CI 1.14–15.05, P = 0.03) were significantly increased
in patients treated with angiogenesis inhibitors. VEGF
is also a vital factor in angiogenesis in normal tissues.
Consequently, anti-angiogenic agents can destroy the
network of capillaries in healthy tissues, and this is
the major reason underlying the adverse reactions of
these drugs. In this meta-analysis, the safety of angio-
genesis inhibitors was similar to previous results for
non-small cell lung carcinoma. Gastrointestinal per-
foration and diarrhea are due to damage to the blood
flow in normal tissues by angiogenesis inhibitors and
lead to intestinal ischemia and necrosis, resulting in
GI perforation and diarrhea. Hand-foot syndrome, a
type of skin toxicity, is a known adverse reaction of
angiogenesis inhibitors, although the mechanism of
this reaction is unknown, it may be associated with
the effects of angiogenesis inhibitors on endothelial
cells, resulting in vascular bed degradation. The hands
and feet are rich in capillaries and capillary degrad-
ation is likely to lead to abnormal sensation and
changes in the skin.
Although the toxicity profiles of biologics (bevacizu-
mab, ramucirumab) and small molecule TKIs (afatinib,
sunitinib, and TSU-68) overlap but are not the same, we
conducted a subgroup analysis. This analysis showed
that the biologics are more likely to lead to hypertension
(RR 5.87, 95 % CI 3.34–10.34, P < 0.0001, Additional file 3:
Table S4), neutropenia (RR 1.56, 95 % CI 1.27–1.93, P <
0.0001, Additional file 3: Table S4), diarrhea (RR 1.83, 95
% CI 1.14–2.94, P = 0.01, Additional file 3: Table S4), and
gastrointestinal perforation (RR 4.14, 95 % CI 1.14–10.09,
P = 0.03, Additional file 3: Table S4), while small molecule
TKIs are more likely to lead to hand-foot syndrome (RR
7.70, 95 % CI 1.83–32.39, P = 0.005, Additional file 4:
Table S3) and thrombocytopenia (RR 0.68, 95 % CI
0.46–1.00, P = 0.04, Additional file 4: Table S3).
Although angiogenesis inhibitors can improve OS and
PFS and achieve a better response rate in advanced GC,
the clinical effect is quite different in individuals due to
heterogeneity of the tumor. It is unclear which patients
benefit most from angiogenesis inhibitors. In an effort to
limit the toxicity and cost of therapy, a large number of
basic and clinical studies need to be conducted, in order
to identify biomarkers which can be used to predict effi-
cacy and choose the most suitable patients to reduce the
blindness of clinical medication.
There are many limitations in this meta-analysis.
Firstly, a small number of trials were included, and there
were no subgroups related to tumor pathological staging
or pathological types. Moreover, the subgroup analysis
included in the literature was limited to one type of
angiogenesis inhibitor, and the conclusions were limited.
Secondly, the differences between statistical quality,
follow-up period, courses, and race in patients receiving
angiogenesis inhibitors resulted in heterogeneity.
Thirdly, the angiogenesis inhibitors included mainly tar-
geted VEGF and its receptor family, thus the conclusions
do not cover all types of angiogenesis inhibitors. Finally,
this is a trial-level meta-analysis based on studies and
not on individual patient data. Confounding variables
such as patient co-morbidities, extent of disease, and dif-
ferences in other possible prognostic factors could not
be incorporated into this analysis. Therefore, future re-
search should focus on high-quality studies and clinical
features in patients with comprehensive evaluation, thus
resulting in more standardized research and more accur-
ate conclusions.
Conclusions
Anti-angiogenic treatment was better than non-anti-
angiogenic treatment in terms of OS, PFS, ORR, and
DCR in patients with advanced GC. Further studies are
needed to explore the timing and potentially predictive
biomarkers of angiogenesis inhibitors to improve the se-
lection of patients and improve clinical benefit.
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